Sanofi plans to invest at least $20 billion in the United States through 2030 to boost manufacturing and research, joining ...

Sanofi said it will invest at least $20 billion in the US through 2030, joining other pharmaceutical companies boosting their ...

(Reuters) -French drugmaker Sanofi said on Wednesday it plans to invest at least $20 billion in the United States through ...

Sanofi (SNY) commits $20B to U.S. research & manufacturing by 2030, boosting R&D & partnerships amidst industry-wide ...

Add Sanofi to the list of drugmakers committing billions to bolster their operations in the United States as President Donald ...

Sanofi India's EBITDA rose 25% to ₹171.9 crore in Q4, with margins improving to 32.1%. Shares closed 2.3% higher at ₹6,066.55 ...

Food allergy in children with atopic dermatitis is associated with an increased risk for asthma, allergic rhinitis, and ...

Sanofi announced plans to invest “at least” $20 billion in the US through 2030, following similar commitments made by several ...

The Health Sciences Authority (HSA) has approved Dupixent (dupilumab) for adults as an add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterized by ...

Therini Bio anticipates using the proceeds to fund Phase 1b trials evaluating its lead candidate, THN391, for the treatment of Alzheimer's Disease (AD) and Diabetic Macular Edema (DME), as well as ...

Asian stocks saw muted trade as investors sought clarity following a US market surge that erased year-to-date losses, fueled ...

The Unified Patent Court (UPC) has quickly become an important forum for pharmaceutical and biotech patent disputes in Europe ...